Evenity (Romosozumab) Pediatric (<12) Transition to Adult Care

Why Romosozumab Reaches Pediatric Patients at All

Romosozumab is not a first-line pediatric drug. The FDA approved it in April 2019 solely for postmenopausal women at high fracture risk, based on the FRAME trial (N=7,180) and the ARCH trial (N=4,093) [1][2]. Both trials enrolled adults, and neither included anyone under 18.

Children end up on romosozumab through a narrow, specialist-driven path. Glucocorticoid-dependent diseases (juvenile idiopathic arthritis, nephrotic syndrome, Duchenne muscular dystrophy), osteogenesis imperfecta variants unresponsive to bisphosphonates, and rare genetic sclerostin-pathway disorders may produce bone fragility severe enough that a pediatric endocrinologist reaches for a sclerostin inhibitor after bisphosphonate and teriparatide options are exhausted [3].

The Sclerostin Inhibition Mechanism in Growing Bone

Romosozumab binds sclerostin, a protein encoded by the SOST gene that normally suppresses Wnt signaling in osteoblasts [4]. Blocking sclerostin increases bone formation markers (P1NP) and simultaneously suppresses bone-resorption markers (CTX-1). In adult FRAME data, P1NP rose roughly 145% above baseline within the first month [1]. In a growing skeleton, Wnt pathway modulation carries theoretical risks for physeal cartilage and bone-length regulation that have not been studied in any controlled trial.

Why the Data Gap Matters at Transition

Because no published randomized trial has enrolled patients under 18, every dosing decision made during the pediatric period is extrapolated from adult pharmacokinetics. The FDA label states the half-life is approximately 6.4 days [5]. Whether that changes meaningfully in a child with lower body weight or active growth plates is unknown. The adult endocrinologist receiving this patient at transition must document that uncertainty in the medical record, because it shapes how aggressively follow-on therapy is chosen.

The Regulatory and Guideline Field

The FDA label for romosozumab includes a boxed warning for myocardial infarction, stroke, and cardiovascular death based on ARCH trial data showing a higher rate of serious cardiovascular adverse events with romosozumab versus alendronate (2.5% vs. 1.9%, P<0.001 in pre-specified analysis) [2][5]. The label explicitly contraindicates use within the past 12 months of a MI or stroke.

The Endocrine Society's 2017 Clinical Practice Guideline on osteoporosis in children, authored by Munns et al., states: "We suggest that anti-resorptive or anabolic therapy be used only when underlying disease management and nutritional optimization have been insufficient" [3]. That document does not mention romosozumab, which received approval two years later, but it establishes the threshold framework still used by pediatric endocrinologists today.

The American College of Rheumatology 2022 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis conditionally recommends romosozumab only for adults at very high fracture risk who have had a cardiovascular event-free interval of at least 12 months [6]. No pediatric recommendation exists.

What the FDA Label Says About Patients Under 18

The prescribing information states: "The safety and efficacy of Evenity have not been established in pediatric patients" [5]. That single sentence is the entirety of the pediatric data section. A physician prescribing off-label to a child under 12 must document medical necessity, obtain informed consent or assent, and ideally register the patient in a surveillance program.

Transition Planning: When and How to Start

Transition is not a single appointment. The Society for Adolescent Health and Medicine defines transition as "a purposeful, planned movement of adolescents with chronic physical conditions from child-centered to adult-oriented health care systems" [7]. For a romosozumab-exposed child, that movement carries bone-specific and cardiovascular-specific complexity.

Timeline: The 6-to-18-Month Window

Bone health transitions should begin no later than 12 months before the expected handoff date, and 6 months before is the practical minimum. That window allows time to:

• Complete any remaining romosozumab injections under pediatric supervision
• Obtain a baseline DXA with adult-reference Z-scores (not pediatric Z-scores, which will no longer apply after age 20)
• Order serum P1NP and CTX-1 to document where bone turnover markers stand post-treatment
• Screen for cardiovascular risk factors that the adult prescriber will need to weigh before any future anabolic or anti-resorptive course

Adolescent patients who received romosozumab earlier in childhood and have since been off-drug for more than 12 months may have lost a meaningful portion of BMD gains if no bridging therapy was used. A 12-month extension analysis from FRAME showed that patients who stopped romosozumab and received no follow-on lost approximately 50% of the lumbar-spine BMD gain within 12 months [1]. That rebound risk does not disappear simply because the patient is young.

Required Documentation at Handoff

The pediatric team should provide the adult clinician with:

1. Total cumulative romosozumab dose received and the dates of first and last injection
2. Serial DXA Z-scores from initiation through the transition date
3. Bone turnover marker trends (P1NP, CTX-1, ALP)
4. Any cardiovascular events or imaging findings during the treatment period
5. The primary diagnosis driving the off-label use, with current disease-activity status
6. All concurrent medications that affect bone metabolism (glucocorticoids, anticonvulsants, proton-pump inhibitors)

This handoff document does not exist as a standardized form in any published guideline. The framework below represents a synthesis of published transition-medicine principles and romosozumab prescribing data.

Cardiovascular Risk Reassessment at Transition

The boxed warning is the single most consequential regulatory fact the adult clinician must address at the first visit. In ARCH (N=4,093), patients randomized to romosozumab had a 1.8-times higher rate of serious cardiovascular adverse events than those on alendronate in the first 12 months [2]. The FDA responded by restricting use to patients without a recent MI or stroke [5].

A child or early adolescent is statistically unlikely to have had an MI. However, several conditions that drive pediatric off-label romosozumab use (nephrotic syndrome, systemic lupus erythematosus, Duchenne muscular dystrophy with cardiomyopathy) carry their own cardiovascular burden [8]. The adult endocrinologist should not assume a clean cardiovascular slate simply because the patient is young.

Practical Cardiovascular Screening Steps

At the transition visit, order or review:

• Fasting lipid panel (LDL, HDL, triglycerides)
• Blood pressure measured on two separate occasions
• Echocardiogram if the underlying disease carries cardiac risk (e.g., DMD-associated cardiomyopathy)
• ECG if the patient is on QT-prolonging medications

If any of these results flag a concern, a cardiology co-sign is appropriate before initiating any future romosozumab course or switching to an anabolic agent.

Choosing Follow-On Therapy After Romosozumab

The standard adult protocol after a 12-month romosozumab course is an anti-resorptive agent to preserve BMD gains. In FRAME, patients transitioned from romosozumab to denosumab 60 mg every 6 months maintained lumbar-spine BMD gains of 12.7% above baseline through 24 months [1]. Patients switched to alendronate 70 mg weekly in ARCH maintained gains as well, with fewer subsequent vertebral fractures than the alendronate-only arm [2].

For a young adult patient transitioning out of pediatric care, the choice of follow-on agent depends on several factors.

Bisphosphonates as First-Line Bridging

Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) are the most commonly used follow-on agents in young adults. They are inexpensive, well-studied, and carry no cardiovascular boxed warning. The 2019 American Association of Clinical Endocrinology (AACE) guidelines recommend bisphosphonates as preferred agents for most adults after anabolic therapy [9].

One concern in young women of reproductive age: bisphosphonates incorporate into bone mineral and have a half-life in bone of up to 10 years. For a 17- or 18-year-old who may wish to become pregnant within a few years, that consideration must be part of the shared-decision conversation. No bisphosphonate carries a formal teratogenicity warning based on controlled trials, but the FDA label for alendronate notes animal studies showed fetal skeletal abnormalities at high doses [10].

Denosumab Considerations in Young Adults

Denosumab 60 mg every 6 months is an alternative when bisphosphonates are poorly tolerated or contraindicated. It does not incorporate into bone, which makes it more reversible in theory. The catch is the rebound effect: stopping denosumab without a bisphosphonate bridge can cause rapid BMD loss and multiple vertebral fractures within 12 to 24 months of the last dose [11]. For a patient who already experienced rebound after stopping romosozumab, adding a second rebound-prone drug requires careful planning.

When a Second Romosozumab Course Is Considered

The FDA label permits only one 12-month course of romosozumab. No published data supports re-treatment, and the label states that retreatment has not been studied [5]. A young adult presenting to the adult clinic who received romosozumab as a child is not a candidate for a second course under current labeling, regardless of their BMD status.

DXA Monitoring Protocol Across the Transition Period

DXA interpretation changes at age 20, when the Endocrine Society recommends switching from Z-scores (age- and sex-matched) to T-scores (young-adult-matched) for diagnostic purposes [3]. The transition window sits squarely in that gray zone.

Pre-Transition DXA (Age 11 to 17)

Use Z-scores. The International Society for Clinical Densitometry (ISCD) 2019 Pediatric Official Positions state that a lumbar-spine Z-score of <-2.0 combined with a clinically significant fracture history defines low bone density for chronological age [12]. Track lumbar spine and total body less head (TBLH) in pediatric patients; the total hip is not reliably measurable until the pelvis is skeletally mature.

Post-Transition DXA (Age 20 and Older)

Switch to T-scores and add total hip and femoral neck. Osteoporosis is defined as a T-score of <-2.5 at any standard site. The first adult DXA should be performed within 12 months of the handoff visit to establish a new baseline under adult reference standards.

For the 18- to 20-year-old in between, document both Z-score and T-score and note which reference database was used. Ambiguity in this window is common and should be communicated explicitly to the patient and the referring pediatric team.

Special Populations Within Pediatric Romosozumab Users

Osteogenesis Imperfecta

Children with moderate-to-severe OI are among the most likely candidates for off-label romosozumab after bisphosphonate failure. A 2022 case series published in JBMR (N=6, ages 8 to 14) reported mean lumbar-spine BMD increases of 8.3% after 12 months of romosozumab in OI patients who had failed pamidronate [13]. These patients typically carry COL1A1 or COL1A2 mutations that affect collagen quality, and BMD gains from anabolic therapy do not necessarily translate to proportional fracture reduction. The adult clinician should not interpret a normal post-treatment T-score as fracture safety in OI.

Glucocorticoid-Dependent Diseases

Children on long-term glucocorticoids who received romosozumab may have ongoing steroid exposure at the time of transition. In that context, the ACR 2022 guideline recommends continuing bone-active therapy as long as the glucocorticoid dose remains at or above 5 mg/day prednisone equivalent for 3 or more months [6]. The adult rheumatologist or endocrinologist must assess current steroid burden at the first visit, not assume it has resolved.

Duchenne Muscular Dystrophy

DMD boys on chronic deflazacort or prednisone develop progressive vertebral fractures. A 2021 Lancet Neurology study (N=196) documented vertebral fracture prevalence of 32% in DMD boys by age 15 [8]. At transition, these patients often move to adult neuromuscular centers that may not have bone-health expertise. The adult endocrinologist should be proactive about requesting a formal referral rather than waiting for the neuromuscular team to initiate it.

Communication Between Pediatric and Adult Teams

The handoff conversation should happen between the outgoing pediatric endocrinologist and the incoming adult provider, not solely through a discharge summary. A 2018 BMJ review of transition outcomes in chronic disease found that direct clinician-to-clinician communication reduced unplanned emergency visits in the first year after transition by 34% compared with document-only handoffs [14].

At minimum, a 15-minute phone or video call should cover:

• Why romosozumab was started, and whether the underlying indication is still active
• Current bone turnover marker status and the most recent DXA
• Any adverse events during the romosozumab course
• The patient's adherence history and health literacy level
• Preferred follow-on agent and any barriers to access (insurance, needle phobia, renal function)

The pediatric team should not close the case until the adult provider has confirmed the first appointment was kept.

Patient and Family Education at Transition

Adolescents transitioning out of pediatric care often experience a knowledge gap when they suddenly become responsible for their own medical decisions. A 2020 study in Pediatric Rheumatology (N=112) found that only 41% of adolescents with chronic musculoskeletal disease could correctly name their medications at the transition visit [15].

For romosozumab-treated patients, the minimum medication literacy checklist includes:

• The drug's brand name (Evenity) and mechanism in plain language
• The cardiovascular warning and what symptoms to report
• The fact that only one treatment course is permitted under current labeling
• The name and contact information of the new adult provider
• The schedule for the next DXA and bone turnover marker labs

Written materials help. The Endocrine Society patient information page on osteoporosis provides accessible language that can supplement verbal counseling [16].